Employees: 1,144
Size Shanghai New World (600628.SS) is a China Health Care company (Medical Distributors) with a market value of $573M, the 3363rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.99 on 18 Nov 2026.
Performance Over six months the shares fell 10.3%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 1.6% over the last twelve months (peer median +3.9%); the operating margin is 6.0% (peer median 1.9%).
Valuation It trades at 2.1× enterprise value to sales against a peer median of 1.0× (3rd most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.1 points below its cost of capital (5.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.09B | CN¥1.09B | CN¥1.11B | CN¥1.12B | CN¥839M |
| Revenue growth | — | -2% | -1% | +34% | — |
| Gross profit | CN¥584M | CN¥446M | CN¥443M | CN¥428M | CN¥216M |
| EBITDA | n/a | CN¥230M | CN¥248M | CN¥246M | CN¥78.2M |
| Net income | CN¥58.9M | CN¥66.7M | CN¥70.0M | CN¥31.7M | -CN¥52.0M |
| Free cash flow | CN¥68.9M | CN¥25.0M | CN¥179M | CN¥179M | CN¥13.1M |
| Capital expenditure | CN¥132M | CN¥159M | CN¥161M | CN¥145M | CN¥35.0M |
| Total debt | CN¥475M | CN¥542M | CN¥572M | CN¥598M | CN¥638M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600628.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.7% | -4.1% | 11th highest of 21 |
| 6-month return | -10.3% | -2.3% | 9th lowest of 21 |
| Distance from 52-week high | -38.7% | -20.5% | 7th lowest of 21 |
| Revenue growth (TTM) | -1.6% | +3.9% | 5th lowest of 21 |
| Operating margin | 6.0% | 1.9% | 5th highest of 21 |
| EV / Sales | 2.1× | 1.0× | 3rd most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -1.6% | 0.0% | 6th least demanding of 16 |
| Growth delivered (Del g) | +1.0% | +5.7% | 4th lowest of 16 |
| Hurdle (Req g minus delivered) | -2.6 pp | -5.3 pp | 6th most demanding of 16 |
| ROIC minus cost of capital | -0.1 pp | -0.5 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | 2.1× | -1.6% | +1.0% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 0.1× | -6.2% | +3.8% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | 0.7× | 13.1% | +7.5% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | 1.1× | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | 4.3× | n/a | n/a |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 0.3× | 5.3% | +8.1% |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | 288.8× | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | 0.6× | 58.3% | -7.8% |
| Excelsior Medical 4104.TW | Taiwan | $404M | +5% | +11% | 8% | 1.4× | -1.2% | +5.7% |
| Vital KSK 3151.T | Japan | $399M | -1% | +3% | 0% | 0.1× | 4.7% | +2.6% |
| Shanghai Haohai Biological Technology 688366.SS | China | $878M | -24% | -9% | -2% | 1.8× | 16.9% | +13.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 1.2× | 24.7% | +29.9% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Shanghai Universal Biotech 301166.SZ | China | $337M | -15% | +15% | -4% | 1.0× | n/a | n/a |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Nagaileben 7447.T | Japan | $319M | 0% | +1% | 21% | 1.6× | -12.7% | -0.4% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 0.6× | -6.9% | +1.2% |